{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T20:31:09Z","timestamp":1792528269143,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.semarthrit.2026.152989","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T06:53:49Z","timestamp":1776754429000},"page":"152989","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Superior drug retention of selective JAK1 inhibitors compared to pan-JAK inhibitors in rheumatoid arthritis: A meta-analysis of real-world evidence"],"prefix":"10.1016","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4213-1909","authenticated-orcid":false,"given":"Young Ho","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwan Gyu","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2026.152989_bib0001","doi-asserted-by":"crossref","first-page":"166","DOI":"10.4078\/jrd.2024.0151","article-title":"Current state and future directions of basic research in rheumatoid arthritis","volume":"32","author":"Ghang","year":"2025","journal-title":"J Rheum Dis"},{"key":"10.1016\/j.semarthrit.2026.152989_bib0002","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","article-title":"Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial","volume":"390","author":"Fleischmann","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2026.152989_bib0003","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus Placebo or Adalimumab in rheumatoid arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2026.152989_bib0004","doi-asserted-by":"crossref","first-page":"252","DOI":"10.4078\/jrd.2025.0039","article-title":"Rheumatoid factor and anti-cyclic citrullinated peptide antibody levels decline in rheumatoid arthritis patients treated with Janus kinase inhibitors or biological disease-modifying anti-rheumatic drugs","volume":"32","author":"Kim","year":"2025","journal-title":"J Rheum Dis"},{"key":"10.1016\/j.semarthrit.2026.152989_bib0005","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","article-title":"Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study","volume":"393","author":"Smolen","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2026.152989_bib0006","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1136\/annrheumdis-2020-219214","article-title":"Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial","volume":"80","author":"Combe","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2026.152989_bib0007","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with Tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2026.152989_bib0008","doi-asserted-by":"crossref","first-page":"182","DOI":"10.4078\/jrd.2024.0130","article-title":"Change of autoantibody levels in established rheumatoid arthritis patients treated by biological disease-modifying anti-rheumatic drugs -the AIRTIGHT study","volume":"32","author":"Anno","year":"2025","journal-title":"J Rheum Dis"},{"key":"10.1016\/j.semarthrit.2026.152989_bib0009","doi-asserted-by":"crossref","first-page":"113","DOI":"10.4078\/jrd.2024.0104","article-title":"Risk of acute myocardial infarction associated with anti-rheumatic agents in patients with rheumatoid arthritis: a nationwide population-based case-control study","volume":"32","author":"Ahn","year":"2025","journal-title":"J Rheum Dis"},{"key":"10.1016\/j.semarthrit.2026.152989_bib0010","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","article-title":"The emerging safety profile of JAK inhibitors in rheumatic disease","volume":"13","author":"Winthrop","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.semarthrit.2026.152989_bib0011","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.semarthrit.2026.152989_bib0012","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0140-6736(04)17670-8","article-title":"External validity of randomised controlled trials: \"to whom do the results of this trial apply?\"","volume":"365","author":"Rothwell","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2026.152989_bib0013","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4078\/jrd.2024.0072","article-title":"Assessment of disease activity and quality of life of Korean patients with rheumatoid arthritis","volume":"32","author":"Lee","year":"2025","journal-title":"J Rheum Dis"},{"key":"10.1016\/j.semarthrit.2026.152989_bib0014","doi-asserted-by":"crossref","DOI":"10.1186\/ar2944","article-title":"The loss of health status in rheumatoid arthritis and the effect of biologic therapy: a longitudinal observational study","volume":"12","author":"Wolfe","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2026.152989_bib0015","first-page":"1457","article-title":"Evaluation of real-world experience with Tofacitinib compared with Adalimumab, Etanercept, and Abatacept in RA patients with 1 previous biologic DMARD: data from a U.S. Administrative Claims database","volume":"22","author":"Harnett","year":"2016","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.semarthrit.2026.152989_bib0016","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.semarthrit.2026.152989_bib0017","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"10.1016\/j.semarthrit.2026.152989_bib0018","series-title":"Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","author":"Wells","year":"2000"},{"key":"10.1016\/j.semarthrit.2026.152989_bib0019","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.semarthrit.2026.152989_bib0020","doi-asserted-by":"crossref","first-page":"122","DOI":"10.4078\/jrd.2024.0103","article-title":"Circulating VEGF levels and genetic polymorphisms in Beh\u00e7et's disease: a meta-analysis","volume":"32","author":"Lee","year":"2025","journal-title":"J Rheum Dis"},{"key":"10.1016\/j.semarthrit.2026.152989_bib0021","doi-asserted-by":"crossref","first-page":"48","DOI":"10.4078\/jrd.2024.0095","article-title":"Associations between circulating interleukin-18 levels and adult-onset Still's disease: a meta-analysis","volume":"32","author":"Lee","year":"2025","journal-title":"J Rheum Dis"},{"key":"10.1016\/j.semarthrit.2026.152989_bib0022","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.semarthrit.2026.152989_bib0023","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"key":"10.1016\/j.semarthrit.2026.152989_bib0024","first-page":"1455","article-title":"Effectiveness and safety comparison among four different JAK inhibitors in rheumatoid arthritis: a real-life, single-center study","volume":"44","author":"Benucci","year":"2024","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.semarthrit.2026.152989_bib0025","first-page":"1234","article-title":"Higher drug survival of upadacitinib compared to tofacitinib in patients with rheumatoid arthritis: a real-world multi-center study","volume":"42","author":"Donzella","year":"2024","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2026.152989_bib0026","first-page":"89","article-title":"Two-year retention rates of JAK inhibitors in rheumatoid arthritis: data from the BIOBADASER registry","volume":"26","author":"Farnos","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2026.152989_bib0027","first-page":"187","article-title":"Comparative effectiveness of JAK inhibitors in rheumatoid arthritis: a retrospective cohort study in tertiary care","volume":"20","author":"Ramirez Huaranga","year":"2024","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.semarthrit.2026.152989_bib0028","unstructured":"Saito K., Tanaka Y., Matsumoto I. Superior retention of upadacitinib versus other JAK inhibitors in patients with rheumatoid arthritis: analysis of the Japanese ANSWER cohort 2024:A567."},{"key":"10.1016\/j.semarthrit.2026.152989_bib0029","first-page":"245","article-title":"Real-world comparative effectiveness of tofacitinib, baricitinib, and upadacitinib in rheumatoid arthritis: a Medicare claims analysis","volume":"77","author":"Curtis","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2026.152989_bib0030","first-page":"789","article-title":"Drug survival of JAK inhibitors in rheumatoid arthritis: results from a multicenter Spanish registry","volume":"64","author":"Leon","year":"2025","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2026.152989_bib0031","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1159\/000527186","article-title":"Relative remission and low disease activity rates of Tofacitinib, Baricitinib, Upadacitinib, and Filgotinib versus Methotrexate in patients with disease-modifying antirheumatic drug-naive rheumatoid arthritis","volume":"108","author":"Lee","year":"2023","journal-title":"Pharmacology"},{"key":"10.1016\/j.semarthrit.2026.152989_bib0032","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/art.41032","article-title":"Upadacitinib versus Placebo or Adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial","volume":"71","author":"Fleischmann","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2026.152989_bib0033","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1136\/annrheumdis-2019-215764","article-title":"Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response","volume":"78","author":"Fleischmann","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2026.152989_bib0034","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1002\/art.40189","article-title":"Herpes zoster and Tofacitinib: clinical outcomes and the risk of concomitant therapy","volume":"69","author":"Winthrop","year":"2017","journal-title":"Arthritis Rheumatol"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017226000788?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017226000788?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:58:46Z","timestamp":1789667926000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017226000788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":34,"alternative-id":["S0049017226000788"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2026.152989","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Superior drug retention of selective JAK1 inhibitors compared to pan-JAK inhibitors in rheumatoid arthritis: A meta-analysis of real-world evidence","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2026.152989","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"152989"}}